Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is mucinous tubular and spindle cell carcinoma (kidney)?
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare type of kidney cancer named for what it looks like under the microscope: small tube-like (tubular) structures, spindle-shaped cells, and a background of mucin (a gel-like substance). It is most often found in middle-aged adults and more commonly in women. The great majority of these tumors are low-grade and slow-growing, with an excellent long-term outlook — most patients are cured by surgery alone. MTSCC is usually discovered incidentally, when a scan done for another reason finds a kidney mass. Because it can resemble another kidney cancer (papillary renal cell carcinoma) under the microscope, expert pathology and sometimes molecular testing are used to confirm the diagnosis. A small minority of cases are higher-grade or 'sarcomatoid' and behave more aggressively, but these are the exception.
The main types
Doctors group mucinous tubular and spindle cell carcinoma (kidney) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Classic (low-grade) MTSCC | The usual form — a slow-growing, low-grade tumor with an excellent outlook, typically cured by surgery alone. |
| High-grade / sarcomatoid MTSCC | An uncommon, more aggressive version with a greater chance of spreading. It is treated more intensively and followed closely. |
Staging, in plain terms
MTSCC is staged with the standard TNM system for kidney cancers — the size of the tumor and whether it stays within the kidney (T), spread to nearby lymph nodes (N), and spread to distant organs (M). Because most cases are low-grade and confined to the kidney when found, they are usually early-stage with an excellent outlook. The grade (how aggressive the cells look) is also important, since the rare high-grade tumors behave more aggressively.
| Kidney-cancer (renal cell) TNM | What it generally means |
|---|---|
| Stage I–II (confined to the kidney) | The tumor is within the kidney. Treated with surgery to remove the tumor (or the kidney), usually curing the cancer. |
| Stage III (local spread) | The tumor extends into nearby tissue or a lymph node. Treated with surgery, with closer follow-up afterward. |
| Stage IV (metastatic) | The cancer has spread to distant organs — uncommon for this tumor. Treated with systemic therapy, surgery for selected sites, and radiation to relieve symptoms or treat limited spread. |
The standard of care
Mucinous Tubular and Spindle Cell Carcinoma (Kidney) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (the main treatment)
Removing the tumor — by taking out just the tumor (partial nephrectomy) when possible, or the whole kidney (radical nephrectomy) — is the primary treatment and cures most cases.
Active surveillance (selected small tumors)
For very small tumors, especially in older patients or those with other health problems, careful monitoring with scans is sometimes an option instead of immediate surgery.
Systemic therapy for advanced disease
For the rare cases that spread, treatments used for other kidney cancers — targeted drugs and immunotherapy — are considered, often guided by clinical trials given how uncommon this tumor is.
Radiation therapy (selective)
Radiation is not part of routine treatment for localized disease, but focused radiation can treat metastatic spots — such as in bone — or relieve symptoms in advanced cases.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide. For mucinous tubular and spindle cell carcinoma, surgery is the main treatment and usually cures the disease, so radiation is not part of routine care for tumors confined to the kidney. Where radiation helps is in the uncommon situations where the cancer spreads or surgery isn't possible: focused stereotactic radiation (SBRT) can precisely treat a small number of metastatic spots, such as in bone or lung, and palliative radiation can relieve symptoms like pain. Kidney cancers were once thought resistant to radiation, but modern high-dose, tightly focused techniques control tumors more effectively than older methods. Radiation is painless during delivery, given over one or a few sessions for focused treatment, and external-beam treatment leaves no radioactivity in the body.
The main ways radiation is delivered for mucinous tubular and spindle cell carcinoma (kidney):
Stereotactic body radiation (SBRT)
Focused high-dose radiation can precisely treat a small number of metastatic spots (for example in bone or lung) or, occasionally, a kidney tumor in a patient who can't have surgery.
Palliative external-beam radiation
Shaped beams relieve symptoms such as pain from areas of spread, improving comfort in advanced disease.
Image-guided radiation
Daily imaging confirms the target's position so the dose is delivered accurately while sparing the remaining kidney and nearby organs.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Generally excellent outcomes: Clinical series confirm that most mucinous tubular and spindle cell carcinomas are low-grade and cured by surgery, with very good long-term survival, while a small subset with high-grade or sarcomatoid features behaves more aggressively.[1]
Urology and kidney-cancer pathology outcome series
Distinct molecular profile: Studies identified characteristic chromosomal losses that help distinguish MTSCC from papillary renal cell carcinoma, refining diagnosis and explaining its generally indolent behavior.[2]
Modern Pathology and genomic analyses of renal tumors
SBRT for kidney cancer and metastases: Trials show stereotactic radiation can effectively control primary kidney tumors in non-surgical patients and treat limited metastatic disease, supporting its selective use in rare kidney cancers like MTSCC.[3]
International kidney SBRT consortium (IROCK) and related studies
Common questions
Is mucinous tubular and spindle cell carcinoma dangerous? Most cases are low-grade and slow-growing, with an excellent outlook — the majority of patients are cured by surgery alone. A small minority are high-grade or 'sarcomatoid' and behave more aggressively, needing more intensive treatment and close follow-up. Your team bases the plan on your tumor's grade and stage.
Why does it need expert pathology? Under the microscope, MTSCC can resemble papillary renal cell carcinoma, a different kidney cancer. Telling them apart — sometimes with molecular testing — matters because it confirms the generally favorable outlook and guides the right treatment and follow-up.
Will I need radiation? Probably not for a tumor confined to the kidney, since surgery is the main treatment and usually curative. Radiation is reserved for the uncommon situations where the cancer spreads or surgery isn't possible — for example, focused radiation to treat a metastatic spot or relieve symptoms.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- Urology and kidney-cancer pathology outcome series (no indexed identifier — see your care team) ↩
- Modern Pathology and genomic analyses of renal tumors (no indexed identifier — see your care team) ↩
- International kidney SBRT consortium (IROCK) and related studies (no indexed identifier — see your care team) ↩